학술논문

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
Document Type
Article
Source
In: Clinical Cancer Research. (Clinical Cancer Research, 2023, 29(5):838-842)
Subject
Language
English
ISSN
15573265
10780432